Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 10, 2021 9:26am
228 Views
Post# 32262904

RE:RE:RE:Cash on Hand

RE:RE:RE:Cash on HandI'm hoping that ATE already sees at least one opportunity to partner wth 3 or 4 companies to bring the first product to market.  Maybe a few options already exist.  A deal(s) with some upfront fees, milestone payments and a double digit royalty.  This is a good starting point as they chat with others and with Big Pharma.

Big Pharma would need to come through with a better offer than the one(s) they already envision.

As additional discussions are had with other players, the bar rises - forcing a full acquisition if there's a certain Big Pharma that really wants to get their hands on OTENA and the future of gaseous mediators.

No idea what kind of deal will be struck.  No idea for how much money.  It is up to ATE to do a good job selling the value of the company - in its present and future states.

Just my opinion.
<< Previous
Bullboard Posts
Next >>